A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Clinical trial NCT00866047 · COMPLETED

Trial details

NCT number: NCT00866047
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin

Start date: 2009-03-01
Primary completion: 2010-08-01
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.